Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing novel therapies for cardiovascular and autoimmune diseases with unmet medical needs. The company's primary approved product is ARCALYST, an interleukin-1 cytokine trap used to treat recurrent pericarditis, Cryopyrin-Associated Periodic Syndromes, and Deficiency of Interleukin-1 Receptor Antagonist in the United States. Kiniksa holds an exclusive license for ARCALYST from Regeneron, excluding the Middle East and North Africa, and has granted exclusive rights in the Asia-Pacific region (excluding Japan) to Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. The company's pipeline includes KPL-387, an investigational monoclonal antibody for recurrent pericarditis currently in Phase 2/3 trials, and KPL-1161, a preclinical asset designed for extended half-life dosing. Kiniksa also holds a worldwide license for abiprubart, a monoclonal antibody targeting the CD40-CD154 interaction, from Beth Israel Deaconess Medical Center. Founded in 2015, the company operates in the United States and collaborates with partners such as Samsung for manufacturing and The Mayo Clinic for clinical research.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage kiniksa.com
Sector Healthcare IR page investors.kiniksa.com/static-files/4ef51fef-a42c-4fbe-a021-e62d6c81c88d
Tags
cardiovascular diseases, autoimmune diseases, monoclonal antibodies, cytokine traps, recurrent pericarditis, immune modulation, specialty pharmacies, clinical trials, ARCALYST, KPL-387, KPL-1161, abiprubart, Regeneron, Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd., Beth Israel Deaconess Medical Center Inc., Samsung, The Mayo Clinic, Johns Hopkins University, Roche, Genentech, vixarelimab, mavrilimumab, KPL-404
Press page —

Metrics

Valuation  
Market cap $ 8.368B
Market cap (USD) $ 8.368B
P/E 75.22
PEG —
P/BV 11.78
P/S 8.85
P/OCF 42.09
P/FCF 42.43
Dividend yield —
Turnover / mcap —
Returns  
ROE 11.7%
ROI 14.4%
ROIC 12.6%
Profit margin 8.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) -31.5%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 27
Quality score 17.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 677.564M 423.239M 270.259M 220.18M 38.544M — — — —
Net profit 59.005M -43.193M 14.084M 183.363M -157.924M -161.381M -161.867M -103.227M -64.873M
Free cash flow 136.417M 25.412M 13.171M 5.702M -126.713M -136.815M -161.572M -86.302M -50.288M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 41.25 19.78 19.17 16.15 23.07 21.02 — 18.85 —
Price performance 12m 1.09 0.03 0.19 -0.3 0.1 — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — 3.99M 12.7M 21.3M 41.7M 15.6M
↳ YoY growth +217.7% +68.0% +96.2% -62.6%
Lease liabilities (USD) — — 3.92M 2.65M 6.99M 6.05M 5.92M 12.3M 9.86M 9.5M
Cash and deposits (USD) 56.1M 45.6M 72M 46.9M 114M 122M 123M 108M 184M 166M
Intangible assets (USD) — — — — 0.00 19.3M 18.3M 17.3M 16.3M 15.3M
Right-of-use assets (USD) — — 3.68M 1.93M 6.57M 5.55M 5.39M 11.9M 10.4M 9.81M
Cash flow detail
Operating cash flow (USD) — -50.2M -81M -158M -137M -126M 5.81M 13.3M 25.7M 138M
Purchases of property, plant and equipment (USD) — -69,000 -5.29M -3.2M -283,000 -415,000 -105,000 -130,000 -277,000 -1.57M
Purchases of intangible assets (USD) — — — — — -20M — — — —
Change in receivables (cash effect) (USD) — — — — — -3.91M -8.68M -8.61M -20.5M 26.1M
Change in inventories (cash effect) (USD) — — — — — -3.68M -17.9M -9.52M 4.76M -28.5M
Change in payables (cash effect) (USD) — 1.01M 8.82M -4.71M -4.97M 1.37M 6.03M 347,000 -6.31M 142,000
Dividends paid (cash effect) (USD) — 0.00 0.00 — — — — — — —
Income taxes paid (cash effect) (USD) — -290,000 -383,000 -1.72M -482,000 -1.28M -10.7M -5.61M -2M -3.01M
Share-based compensation (USD) — 897,000 5.7M 15.1M 20.9M 25.2M 25.1M 27.1M 30.7M 37M
Operating cash flow before change in receivables (USD) — — — — — -122M 14.5M 21.9M 46.1M 112M
Free cash flow (OCF - PPE - intangibles) (USD) — -50.3M -86.3M -162M -137M -147M 5.7M 13.2M 25.4M 136M
Income detail
Research and development expense (USD) — 56.4M 86.6M 135M 112M 99.3M 65.5M 76.1M 112M 96.9M
↳ 5y CAGR +3.0% -2.6% -3.7% -2.9%
Total comprehensive income (USD) — -64.9M -103M -162M -161M -158M 183M 14M -43.4M 59.1M
Comprehensive income to owners (USD) — -64.9M -103M -162M -161M -158M 183M 14M -43.4M 59.1M
Reported Aug 6, 2018 Mar 12, 2019 May 7, 2019 Mar 5, 2020 May 6, 2021 Feb 24, 2022 Mar 2, 2023 Feb 28, 2024 Feb 25, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

10/27/26

Download PDF

– ARCALYST® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion – – KPL-387 pivotal Phase 3 data expected in 2H 2027 – – Conference call and webcast scheduled for 8:30 am ET today –

LONDON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported third quarter 2026 financial results and recent portfolio execution.

“Kiniksa continues to build a leading IL-1α and IL-1β inhibition franchise, driven by the commercialization of ARCALYST in recurrent pericarditis. In the third quarter, strong commercial execution led to gains in patient and physician adoption, resulting in revenue of $286.0 million and positioning ARCALYST to achieve blockbuster status this year,” said Sanj K. Patel, Chairman & Chief Executive Officer of Kiniksa. “Our robust financial position supports continued investment in value creation through ARCALYST, KPL-387, and KPL-1161. We now expect 2026 ARCALYST net sales of between $1.045 and $1.050 billion, up from our previous range of between $980 and $995 million. Additionally, we continue to enroll and dose patients in PASTORALE, the pivotal Phase 3 trial of KPL-387 evaluating once monthly subcutaneous dosing. We expect data in the second half of 2027, with the goal of bringing this important treatment option to patients in the 2028/2029 timeframe. We remain on track to initiate a Phase 1 trial of KPL-1161 by the end of this year.”

Portfolio Execution ARCALYST (IL-1α and IL-1β cytokine trap)

  • ARCALYST net product revenue was $286.0 million for the third quarter of 2026.

  • As of the end of the third quarter of 2026, approximately 23% of the 14,000 annual multiple-recurrence patients were actively on ARCALYST treatment.

  • Since launch, more than 5,450 prescribers have written ARCALYST prescriptions for recurrent pericarditis.

  • As of the end of the third quarter of 2026, average total duration of ARCALYST therapy in recurrent pericarditis was approximately 3 years, in line with the median duration of disease.

KPL-387 (monoclonal antibody IL-1 receptor antagonist)

  • Kiniksa is enrolling and dosing patients in the Phase 3 pivotal trial of KPL-387 in recurrent pericarditis, PASTORALE, and expects data in the second half of 2027.

  • Kiniksa is also conducting a supplemental Phase 2 Transition to KPL-387 Monotherapy Dosing and Administration Study evaluating the transition of patients from standard therapies to KPL-387 monotherapy.

KPL-1161 (Fc-modified monoclonal antibody IL-1 receptor antagonist)

  • Kiniksa expects to initiate a Phase 1 first-in-human clinical trial of KPL-1161 with a target profile of quarterly subcutaneous (SC) dosing by the end of 2026.

Financial Results

  • Total revenue for the third quarter of 2026 was $286.0 million, compared to $180.9 million for the third quarter of 2025.

  • Total operating expenses for the third quarter of 2026 were $231.7 million, compared to $156.8 million for the third quarter of 2025, and comprised the following:

  • Cost of Goods Sold (COGS) expenses of $27.8 million, compared to $20.3 million for the third quarter of 2025. The increase in COGS expenses was primarily due to costs associated with increased sales of ARCALYST.

  • Collaboration expenses of $105.8 million, compared to $63.3 million for the third quarter of 2025. Collaboration expenses are driven primarily by ARCALYST collaboration profitability.

  • Research and Development (R&D) expenses of $32.8 million, compared to $24.2 million for the third quarter of 2025. The increase in R&D expenses was primarily due to increased KPL-387 clinical activity.

  • Selling, General, and Administrative (SG&A) expenses of $65.4 million, compared to $49.1 million for the third quarter of 2025. The increase in SG&A expenses was primarily due to investment associated with the commercialization of ARCALYST.

  • Total operating expenses for the third quarter of 2026 included $13.1 million in non-cash, share-based compensation expense, compared to $10.1 million for the third quarter of 2025.

  • Net income for the third quarter of 2026 was $47.3 million, compared to $18.4 million for the third quarter of 2025.

  • As of September 30, 2026, Kiniksa had $568.8 million of cash, cash equivalents, and short-term investments and no debt.

Financial Guidance

  • Kiniksa expects 2026 ARCALYST net product revenue of between $1.045 billion and $1.050 billion, compared to prior guidance of between $980 million and $995 million.

  • Kiniksa expects 2026 R&D expenses of between $160 million and $170 million and 2026 SG&A expenses of between $270 million and $280 million.

  • Kiniksa expects its current operating plan to remain cash flow positive on an annual basis.

Conference Call Information

  • Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, October 27, 2026, to discuss third quarter 2026 financial results and recent portfolio execution.

  • Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. To access the webcast, please visit the Investors and Media section of Kiniksa’s website. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

About ARCALYST ARCALYST is a weekly, subcutaneously injected recombinant dimeric fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling. ARCALYST was discovered by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug Administration (FDA) for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome, and deficiency of IL-1 receptor antagonist (DIRA). The FDA granted Breakthrough Therapy designation to ARCALYST for the treatment of recurrent pericarditis in 2019 and Orphan Drug exclusivity to ARCALYST in 2021 for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years and older. The European Commission granted Orphan Drug Designation to ARCALYST for the treatment of idiopathic pericarditis in 2021.

IMPORTANT SAFETY INFORMATION ABOUT ARCALYST

  • ARCALYST may affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection).

  • While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel® (etanercept), Humira® (adalimumab), or Remicade® (infliximab), as this may increase your risk of getting a serious infection.

  • Talk with your doctor about your vaccine history. Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST.

  • Medicines that affect the immune system may increase the risk of getting cancer.

  • Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction.

  • Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides.

  • Common side effects include injection-site reactions (which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose.

10/22/26

Download PDF

LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern Time to report its third quarter 2026 financial results and recent portfolio execution.

A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

Every Second Counts! ®

Kiniksa Investor & Media Contact Jonathan Kirshenbaum (781) 829-3949 [email protected]

Print Page

RSS

Email Alerts

Search

Company Logo

Your Opt Out Preference Signal is Honored

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. Cookie Policy

Allow All

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookie List

Clear

checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All

Powered by Onetrust

On October 17, 2026, the Compensation Committee (the “Committee”) of the Board of Directors of Kiniksa Pharmaceuticals International, plc (the “Company”) appointed Ross Moat as President and Chief Operating Officer, effective immediately. Mr. Moat will continue to report to Sanj K. Patel, the Company’s Chairman and Chief Executive Officer. In addition, effective January 1, 2027, the Committee approved increases in Mr. Moat’s annual base salary and annual target bonus to $700,000 and 60% from $650,000 and 55%, respectively. Mr. Moat has served in varying capacities at the Company since June 2019, most recently as the Company’s EVP, Chief Operating Officer. In his current position, Mr. Moat oversees the Company’s commercial, clinical, regulatory and manufacturing operations. Mr. Moat’s full biographical information is disclosed in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 16, 2026. There are no family relationships between Mr. Moat and any director or executive officer of the Company. There are no related party transactions involving Mr.

Prompts

Kiniksa Pharmaceuticals International, plc (ticker KNSA), listed in United States.

Company History

Date Change Detail
Jun 28, 2024 Renamed KINIKSA PHARMACEUTICALS, LTD. → KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC

ETFs Holding Kiniksa Pharmaceuticals International, plc

ETF Weight in ETF Shares Market value As of
EHLS 1.10% 6,312 $ 594.78K Nov 17, 2026
AFSM 0.92% 14,284 $ 1.346M Nov 16, 2026
MMSC 0.58% 3,061 $ 288.438K Nov 16, 2026
HELX 0.34% 1,479 $ 94.582K Jun 30, 2026
SHRT 0.21% 289 $ 27.232K Nov 17, 2026
SEIS 0.17% 15,331 $ 980.417K Jun 30, 2026
AVSC 0.16% 54,420 $ 5.128M Nov 16, 2026
VFMO 0.14% 34,693 $ 2.728M Aug 31, 2026
FFF 0.10% 88 $ 6,565.68 Sep 30, 2026
VFMF 0.09% 11,435 $ 899.134K Aug 31, 2026
DFAS 0.09% 315,332 $ 30.36M Nov 12, 2026
VFQY 0.03% 2,250 $ 176.918K Aug 31, 2026
AVMC 0.02% 957 $ 90.178K Nov 16, 2026
DFAC 0.02% 156,380 $ 15.056M Nov 12, 2026
DCOR 0.01% 48,273 $ 4.648M Nov 12, 2026
DFSU 0.01% 1,652 $ 159.055K Nov 12, 2026
DFAU 0.01% 8,096 $ 779.483K Nov 12, 2026
DFUS 0.01% 12,728 $ 1.225M Nov 12, 2026
EBI 0.00% 36 $ 2,830.68 Aug 31, 2026
AVUS 0.00% 473 $ 44.571K Nov 16, 2026
AVSU 0.00% 49 $ 4,617.27 Nov 16, 2026
AVLC 0.00% 165 $ 15.548K Nov 16, 2026
NTRL 0.00% 1,427 $ 0.00 Nov 16, 2026